Hangzhou, China, Sept. 24, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”),…
Healthcare as the World’s Most Strategic Investment: KFSHRC CEO Calls for Global Collaboration at C3 Japan Summit H.E. Dr. Majid…
- Update based on FDA End-of- Phase 2 meeting outcome - Phase 3 study start accelerated by six months, in…
OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults…
Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation The fund…
Availability of the Q3 2025 Aide mémoire Paris, France – September 24, 2025. Sanofi announced today that its Q3…
NEW YORK, Sept. 23, 2025 /PRNewswire/ -- Luminary Labs is thrilled to announce that it has been awarded new federal…
Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for…
STONY BROOK, NY / ACCESS Newswire / September 23, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the…
Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groupsBoth…